MWN101
/ Minwei Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 31, 2026
A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Phase Ⅱ Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetic Characteristics of MWN101 Injection in the Treatment of Type 2 Diabetes Mellitus.
(ChiCTR)
- P2 | N=105 | Completed | Sponsor: Beijing Friendship Hospital Pinggu Campus,Capital Medical University; Beijing Friendship Hospital Pinggu Campus,Capital Medical University
New P2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 1
Of
1
Go to page
1